Blood component alternatives

Antifibrinolytic drugs such as tranexamic acid and epsilon-aminocaproic acid help prevent clot breakdown. Tranexamic acid has shown benefit in bleeding trauma patients and can also reduce bleeding in surgical and mucosal bleeding settings, although caution is needed in patients at high thrombotic risk. Desmopressin may temporarily improve platelet adhesion in selected platelet function disorders, uraemic platelet dysfunction, or some cases involving antiplatelet drug effect.

Thrombopoietin receptor agonists (listed in Table 1) stimulate platelet production in selected chronic conditions including chronic immune thrombocytopenia (ITP), and some other forms of thrombocytopenia. They may reduce repeated transfusions but are not useful for immediate bleeding because they take time to work. Synthetic platelet substitutes are designed to reproduce one or more essential platelet functions without relying on donor-derived cells. However, most remain in preclinical or early clinical development.

Alternatives to plasma and coagulation factor replacement

Plasma transfusion replaces multiple clotting factors during bleeding or significant coagulopathy. However, fresh frozen plasma needs thawing, may require blood group compatibility, is given in large volumes, and can cause allergic reactions, lung injury, or circulatory overload. Targeted therapy is therefore preferred when a specific defect can be identified. Prothrombin complex concentrates provide vitamin K-dependent clotting factors and are useful for urgent reversal of vitamin K antagonist anticoagulation, but they are not suitable for all coagulopathies and may increase thrombotic risk. Fibrinogen concentrate can treat low fibrinogen during major bleeding, trauma, obstetric haemorrhage, or dilutional coagulopathy. Recent trials and reviews suggest that fibrinogen concentrate, and cryoprecipitate may have comparable effectiveness in selected bleeding settings, although the choice still depends on availability, urgency, cost, guidelines, and testing. Specific factor concentrates and recombinant clotting factors are used when a defined factor deficiency is present, such as haemophilia A or B. They provide more precise replacement than plasma but require accurate diagnosis, monitoring, and awareness of thrombotic risk. Non-transfusion measures also help correct coagulopathy. Vitamin K treats deficiency or warfarin effect, calcium correction supports coagulation during major bleeding, and control of hypothermia, acidosis, and haemodilution improves clot formation. Tranexamic acid may also reduce bleeding by stabilizing clots. Despite these advantages, plasma and coagulation factor alternatives have limitations. Concentrates are expensive, unavailable in some hospitals, or inappropriate when the coagulation abnormality is complex and poorly defined. Some agents carry thrombotic risks, and overcorrection can be harmful. Selection should therefore be guided by the cause of bleeding, laboratory results, urgency, patient condition, and local protocols. BCAs involve ethical, practical, and personal considerations. Patients should receive clear information about transfusion and non-transfusion options, including their benefits, risks, and limitations. Patients who decline transfusion for religious, cultural, or personal reasons require careful planning. Practical limitations, including cost, availability, trained staff, equipment, and institutional protocols, also need to be considered. Decisions regarding BCA use should be guided by diagnosis, laboratory results, bleeding severity, patient condition, and specialist advice. In conclusion, BCAs are an important part of modern transfusion medicine. They reduce dependence on donor blood, improve safety, respect patient choices, and protect limited blood supplies. However, they are not complete replacements in every situation. A planned, individualized, and team-based approach remains the best way to conserve blood safely.